| Symbol | ACRV |
|---|---|
| Name | ACRIVON THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 480 ARSENAL WAY,SUITE 100, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | 6172078979.0 |
| Fax | — |
| — | |
| Website | https://www.acrivon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001781174 |
| Description | Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The companys Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Additional info from NASDAQ: |
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 000686
Read moreTOMSICEK MICHAEL JOHN 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003042
Read moreShacham Sharon 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003041
Read morePalani Santhosh 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003035
Read moreMagovcevic-Liebisch Ivana 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003034
Read moreDiRocco Derek 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003033
Read moreBAUM CHARLES M 🟢 acquired 20.3K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $1.52 Transaction Date: Jun 17, 2026 | Filing ID: 003024
Read more(99% Neutral) ACRIVON THERAPEUTICS, INC. (ACRV) Announces Executive Changes
Read moreBlume-Jensen Peter 🔴 sold 13.7K shares of Acrivon Therapeutics, Inc. (ACRV) at $1.79 Transaction Date: May 21, 2026 | Filing ID: 002652
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06667141 | Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase1 | Specific Advanced Solid Tumors | Recruiting | 2024-10-08 | 2026-12-12 | ClinicalTrials.gov |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase2 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2024-09-25 | 2028-08-23 | ClinicalTrials.gov |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase2 | Endometrial Adenocarcinoma | Recruiting | 2022-08-29 | 2027-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06597565 |
| Gemcitabine | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06597565 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-2316 | Other | Phase PHASE1 | Specific Advanced Solid Tumors | RECRUITING | NCT06667141 |